A multicentre randomised controlled trial of intravenous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)

Michael Absoud, Peter Brex, Olga Ciccarelli, Onyinye Diribe, Gavin Giovannoni, Jennifer Hellier, Rosemary Howe, Rachel Holland, Joanna Kelly, Paul McCrone, Caroline Murphy, Jackie Palace, Andrew Pickles, Michael Pike, Neil Robertson, Anu Jacob and Ming Lim

1Department of Children’s Neurosciences, Evelina Children’s Hospital at Guy’s and St Thomas’ NHS Foundation Trust, King’s Health Partners Academic Health Science Centre, London, UK
2Department of Neurology, King’s College Hospital NHS Foundation Trust, King’s Health Partners Academic Health Science Centre, London, UK
3University College London Institute of Neurology, London, UK
4King’s Clinical Trials Unit, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
5Centre for Neuroscience and Trauma, Blizzard Institute, University of London and Barts Health NHS Trust, London, UK
6Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
7Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
8Department of Neurology, Oxford University Hospitals NHS Trust, Oxford, UK
9Department of Paediatric Neurology, Oxford University Hospitals NHS Trust, Oxford, UK
10Institute of Psychological Medicine and Clinical Neurosciences, Cardiff and Vale University Health Board, Cardiff, UK
11The Walton Centre, Walton Centre NHS Foundation Trust, Liverpool, UK

*Corresponding author ming.lim@gstt.nhs.uk
Declared competing interests of authors: Intravenous immunoglobulin was provided by Biotest AG, Germany, and, should any commercial opportunity arise, the industrial partner has an option for an exclusive licence from the sponsor (Guy’s and St Thomas’ NHS Foundation Trust) and the potential for a revenue-sharing arrangement. Michael Absoud serves on the data safety monitoring board for a study sponsored by Neurim Pharmaceuticals, has received consultation fees from Novartis and is on the editorial advisory board for the International Journal of Language & Communication Disorders. Peter Brex has received fees for speaking and consulting from Biogen Idec, Roche, Sanofi Genzyme, Teva Pharmaceuticals Industries Ltd and Merck Serono. Olga Ciccarelli serves as consultant for Novartis, Biogen Inc. and GE Healthcare and is an Associate Editor of Neurology. Gavin Giovannoni has received consultation and speaking fees from Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme and Synthovia BV and is on the steering committee for studies sponsored by AbbVie, Biogen Idec, Novartis, Teva Pharmaceuticals Industries Ltd and Roche. Jackie Palace serves on the scientific advisory board for the Charcot Foundation, has performed advisory work for Biogen Idec, Merck Serono, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd, Gilenya, Ono Pharmaceutical Co., Primary i-Research, Alexion Pharmaceuticals Inc. and Chugai Pharma Europe, receives research support from Merck Serono, Bayer Schering Pharma, Biogen Idec and Teva Pharmaceuticals Industries Ltd and has received conference expenses from Novartis, Merck Serono and Biogen Idec. Michael Pike has received a meeting support grant from EUROIMMUN. Anu Jacob is supported by the NHS National Specialised Commissioning Group for Neuromyelitis Optica, has been a consultant for Shire, Alexion Pharmaceuticals Inc. and Chugai Pharmaceutical Co. Ltd and has received research funding from Biogen Inc. and Alexion Pharmaceuticals Inc. Ming Lim has received consultation fees from CSL Behring and travel grants from Merck Serono and has been awarded educational grants to organise meetings by Novartis, Biogen Idec, Merck Serono and Bayer.
Plain English summary

Transverse myelitis (TM) is a rare immune disorder that affects the spinal cord. Patients who develop TM can quickly lose the feeling in and the ability to move lower parts of the body (paraplegia). Additionally, the upper body can also be affected (tetraplegia). TM can affect people at any age and can have a significant impact on quality of life and place a large demand on health resources.

Although immune treatments such as steroids, intravenous immunoglobulin (IVIG) and plasma exchange are being used to treat TM, until now, no high-quality trial has been conducted to measure how effective these treatments are when utilised individually or in combination. Therefore, this randomised controlled trial was designed to see whether or not newly diagnosed TM patients would benefit from early treatment with IVIG if added to steroid therapy, which we expect all patients to receive. We measured the effect of treatment using the American Spinal Injury Association (ASIA) Impairment Scale, an outcome measure that has been validated in spinal injury research, and using evaluators who were not aware of the treatment that patients had received (single blind).

After 1 year, despite 15 centres recruiting across the UK, only two patients were randomised. The key reasons for this include the strict inclusion criteria, the short enrolment window, the challenges associated with the use of the ASIA Impairment Scale as the primary outcome measure, an inaccurate estimation of the incidence of TM and the spectrum of severity within the target population and inadequate funding provision for some sites. As 170 cases were required to determine a statistically significant effect of treatment, the study was closed early as this end point would not have been realistically achieved. However, we are now aware of important factors that need to be addressed when undertaking a trial in TM or an allied rare condition.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/129/148. The contractual start date was in June 2014. The draft report began editorial review in October 2016 and was accepted for publication in February 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Absoud et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Health Technology Assessment Editor-in-Chief**

**Professor Hywel Williams**  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

**NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:  
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:**  journals.library@nihr.ac.uk